This study will evaluate the effects of Edenboost Alpha Cleanse, a dietary supplement, on symptoms associated with liver and digestive health. The study is a single-arm, open-label trial in which all 40 enrolled participants will use the test product daily for 12 weeks. Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will undergo blood testing (hepatic function panel) at Baseline and Week 12. Primary outcomes focus on changes in liver function biomarkers, while secondary outcomes capture participants' self-reported experiences of energy levels, abdominal bloating, abdominal pain, fatigue, and nausea.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
All participants receive Edenboost Alpha Cleanse (two capsules once daily with the first meal of the day) for 12 weeks.
Citruslabs
Las Vegas, Nevada, United States
Change in Alanine Aminotransferase (ALT/SGPT)
Change in serum ALT/SGPT level assessed via hepatic function panel blood test at Labcorp
Time frame: Baseline and Week 12
Change in Albumin
Change in serum albumin level assessed via hepatic function panel blood test at Labcorp
Time frame: Baseline and Week 12
Change in Alkaline Phosphatase
Change in serum alkaline phosphatase level assessed via hepatic function panel blood test at Labcorp
Time frame: Baseline and Week 12
Change in Aspartate Aminotransferase (AST/SGOT)
Change in serum AST/SGOT level assessed via hepatic function panel blood test at Labcorp
Time frame: Baseline and Week 12
Change in Bilirubin
Change in serum bilirubin level assessed via hepatic function panel blood test at Labcorp
Time frame: Baseline and Week 12
Change in Total Protein
Change in serum total protein level assessed via hepatic function panel blood test at Labcorp
Time frame: Baseline and Week 12
Change in Self-Reported Abdominal Bloating
Participant-reported change in abdominal bloating assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Abdominal Pain
Participant-reported change in abdominal pain assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Fatigue
Participant-reported change in fatigue assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Nausea
Participant-reported change in nausea assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Self-Reported Energy Levels
Participant-reported change in energy levels assessed via self-reported questionnaire
Time frame: Baseline, Week 4, Week 8, and Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.